Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Sequential Treatment of Pediatric MDD to Increase Remission and Prevent Relapse

This study has been completed.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Graham Emslie, University of Texas Southwestern Medical Center
ClinicalTrials.gov Identifier:
NCT00612313
First received: February 7, 2008
Last updated: December 16, 2014
Last verified: July 2014
Results First Received: July 3, 2014  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Single Blind (Outcomes Assessor);   Primary Purpose: Treatment
Condition: Depression
Interventions: Drug: Fluoxetine
Behavioral: Relapse prevention cognitive behavioral therapy (CBT)

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
200 participants began acute phase open-label treatment with fluoxetine. Of these, 144 entered the randomized control study. Results data presented are for 144 participants randomized.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Continued Medication Alone

n=69 Participants will receive antidepressant treatment with fluoxetine for 30 weeks

Fluoxetine: Participants will take 10 to 40 mg per day of fluoxetine for 30 weeks.

Continued Medication Plus CBT

n=75 Participants will receive antidepressant treatment with fluoxetine for 30 weeks plus relapse prevention cognitive behavioral therapy for the last 24 weeks of treatment

Fluoxetine: Participants will take 10 to 40 mg per day of fluoxetine for 30 weeks.

Relapse prevention cognitive behavioral therapy (CBT): After the first 6 weeks of treatment with fluoxetine, some participants will be assigned to additionally receive relapse prevention CBT for the remaining 24 weeks of treatment. These participants will attend 10 to 12 CBT sessions, during which they will learn specific skills to reduce and prevent the occurrence of residual depressive symptoms.


Participant Flow:   Overall Study
    Continued Medication Alone     Continued Medication Plus CBT  
STARTED     69     75  
COMPLETED     52     62  
NOT COMPLETED     17     13  
Withdrawal by Subject                 6                 9  
Lost to Follow-up                 11                 4  



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Continued Medication Alone

Participants received antidepressant treatment with fluoxetine for 30 weeks

Fluoxetine: Participants will take 10 to 40 mg per day of fluoxetine for 30 weeks.

Continued Medication Plus CBT

Participants received antidepressant treatment with fluoxetine for 30 weeks plus relapse prevention cognitive behavioral therapy for the last 24 weeks of treatment

Fluoxetine: Participants will take 10 to 40 mg per day of fluoxetine for 30 weeks.

Relapse prevention cognitive behavioral therapy (CBT): After the first 6 weeks of treatment with fluoxetine, these participants were assigned to additionally receive relapse prevention CBT for the remaining 24 weeks of treatment. These participants attended 10 to 12 CBT sessions, during which they will learn specific skills to reduce and prevent the occurrence of residual depressive symptoms.

Total Total of all reporting groups

Baseline Measures
    Continued Medication Alone     Continued Medication Plus CBT     Total  
Number of Participants  
[units: participants]
  69     75     144  
Age  
[units: Years]
Mean ± Standard Deviation
  14.2  ± 2.4     13.5  ± 2.7     13.8  ± 2.6  
Gender  
[units: participants]
     
Female     39     38     77  
Male     30     37     67  
Ethnicity (NIH/OMB)  
[units: participants]
     
Hispanic or Latino     20     23     43  
Not Hispanic or Latino     49     52     101  
Unknown or Not Reported     0     0     0  
Race (NIH/OMB)  
[units: participants]
     
American Indian or Alaska Native     1     0     1  
Asian     0     1     1  
Native Hawaiian or Other Pacific Islander     0     0     0  
Black or African American     7     8     15  
White     54     64     118  
More than one race     7     2     9  
Unknown or Not Reported     0     0     0  
Region of Enrollment  
[units: participants]
     
United States     69     75     144  
Baseline CDRS-R [1]
[units: units on a scale]
Mean ± Standard Deviation
  59.2  ± 7.0     56.8  ± 7.1     58.0  ± 7.2  
Baseline CGI Severity [2]
[units: units on a scale]
Mean ± Standard Deviation
  5.3  ± 0.69     5.1  ± 0.7     5.2  ± 0.7  
[1]

Childhood Depression Rating Scale - Revised (CDRS-R) Total score range: 17-113

Scoring thresholds:

>=40: moderate to severe depression; <=28: remission

[2]

Clinical Global Impression - Severity Range: 1-7

  1. Normal, not at all ill
  2. Borderline mentally ill
  3. Mildly ill
  4. Moderately ill
  5. Markedly ill
  6. Severly ill
  7. Among the most extremely ill patients



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Time to Remission   [ Time Frame: 30 weeks ]

2.  Primary:   Relapse   [ Time Frame: Measured at Weeks 12, 18, 24, and 30 ]

3.  Primary:   Remission   [ Time Frame: Measured at Weeks 12, 18, 24, and 30 ]

4.  Secondary:   K-Life (Time Well)   [ Time Frame: 30 weeks ]

5.  Secondary:   Remission   [ Time Frame: Weeks 52 and 78 ]
Results not yet reported.   Anticipated Reporting Date:   09/2014   Safety Issue:   No

6.  Secondary:   Relapse   [ Time Frame: Weeks 52 and 78 ]
Results not yet reported.   Anticipated Reporting Date:   09/2014   Safety Issue:   No


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
  • Primary outcomes based on data through 30 weeks.
  • Participants were not blinded to treatment assignment.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.


Results Point of Contact:  
Name/Title: Dr. Graham Emslie and Dr. Betsy Kennard
Organization: UT Southwestern Medical Center
phone: 214-456-5900
e-mail: beth.kennard@utsouthwestern.edu


Publications of Results:

Responsible Party: Graham Emslie, University of Texas Southwestern Medical Center
ClinicalTrials.gov Identifier: NCT00612313     History of Changes
Obsolete Identifiers: NCT00599300
Other Study ID Numbers: R01 MH039188-01, R01MH039188-01, DSIR 84-CTS
Study First Received: February 7, 2008
Results First Received: July 3, 2014
Last Updated: December 16, 2014
Health Authority: United States: Federal Government